PEN Penumbra Inc

  1. Stocks
  2. Healthcare
  3. NYSE: PEN

Price (delayed)

$319.44

Market cap

$12.58B

P/E Ratio

78.1

Dividend/share

N/A

EPS

$4.09

Enterprise value

$12.59B

?
Relative Growth: Rel. Growth: 48
Relative Strength: Rel. Strength: 56
Relative Valuation: Rel. Valuation: 13
Relative Profitability: Rel. Profitability: 70

Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and ...

Highlights
PEN's gross profit is up by 20% year-on-year and by 4.2% since the previous quarter
PEN's equity is up by 18% year-on-year and by 3.9% since the previous quarter
The price to earnings (P/E) is 82% lower than the 5-year quarterly average of 425.2 but 12% higher than the last 4 quarters average of 70.0
The net income has increased by 9% YoY but it has decreased by 6% from the previous quarter
Penumbra's quick ratio has decreased by 4.5% YoY and by 3.7% QoQ
Sector: Healthcare
Industry: Medical Devices
Website: http://www.penumbrainc.com
Peers: OFIX

Key stats

What are the main financial stats of PEN

PEN stock price

How has the Penumbra stock price performed over time
Intraday
0.02%
1 week
0.33%
1 month
-1.77%
1 year
25.69%
YTD
2.74%
QTD
1.17%

Financial performance

How have Penumbra's revenue and profit performed over time
Revenue
$1.5B
Gross profit
$1.02B
Operating income
$187.34M
Net income
$160.59M
Gross margin
67.8%
Net margin
10.7%
PEN's gross profit is up by 20% year-on-year and by 4.2% since the previous quarter
Penumbra's operating income has increased by 18% YoY
PEN's revenue is up by 18% year-on-year and by 3.5% since the previous quarter
The net income has increased by 9% YoY but it has decreased by 6% from the previous quarter

Price vs fundamentals

How does PEN's price correlate with its fundamentals

Growth

What is Penumbra's growth rate over time

Valuation

What is Penumbra stock price valuation
PEN P/E details
P/E
78.1
P/B
8.21
P/S
8.35
EV/EBIT
61.77
EV/EBITDA
56.98
EV/Sales
8.37
The price to earnings (P/E) is 82% lower than the 5-year quarterly average of 425.2 but 12% higher than the last 4 quarters average of 70.0
PEN's EPS is up by 7% YoY but it is down by 7% QoQ
PEN's equity is up by 18% year-on-year and by 3.9% since the previous quarter
The stock's P/B is 3.4% below its 5-year quarterly average of 8.5
PEN's revenue is up by 18% year-on-year and by 3.5% since the previous quarter
PEN's price to sales (P/S) is 10% lower than its 5-year quarterly average of 9.3

Efficiency

How efficient is Penumbra business performance
The company's return on invested capital fell by 11% YoY and by 7% QoQ
The ROA has contracted by 10% from the previous quarter and by 9% YoY
The ROE has contracted by 10% YoY and by 10% from the previous quarter
PEN's ROS is down by 3.6% QoQ

Dividends

What is PEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PEN.

Financial health

How did Penumbra financials performed over time
Penumbra's total assets has increased by 18% YoY and by 4% from the previous quarter
PEN's total liabilities is up by 17% YoY and by 4.6% from the previous quarter
Penumbra's debt is 86% lower than its equity
PEN's equity is up by 18% year-on-year and by 3.9% since the previous quarter
PEN's debt to equity is down by 18% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.